Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease

Abstract Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population globally. Since liver fibrosis is the most important predictor of liver-related complications in patients with NAFLD, identification of patients with advanced fibrosis among at-risk individuals is an important iss...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Katharine M. Irvine, Satomi Okano, Preya J. Patel, Leigh U. Horsfall, Suzanne Williams, Anthony Russell, Elizabeth E. Powell
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3622a3451cc5424a98c6081d430e546b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3622a3451cc5424a98c6081d430e546b
record_format	dspace
spelling	oai:doaj.org-article:3622a3451cc5424a98c6081d430e546b2021-12-02T10:44:22ZSerum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease10.1038/s41598-021-82315-z2045-2322https://doaj.org/article/3622a3451cc5424a98c6081d430e546b2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82315-zhttps://doaj.org/toc/2045-2322Abstract Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population globally. Since liver fibrosis is the most important predictor of liver-related complications in patients with NAFLD, identification of patients with advanced fibrosis among at-risk individuals is an important issue in clinical practice. Transient elastography is the best evaluated non-invasive method used in referral centres to assess liver fibrosis, however serum-based tests, such as the Enhanced Liver Fibrosis (ELF) score, have a practical advantage as first-line tests due to their wider availability and lower cost. We previously identified matrix metalloproteinase 7 (MMP7) as a serum biomarker of histological advanced fibrosis in a mixed-etiology patient cohort. In this study we aimed to determine the association between MMP7 and fibrosis, assessed by transient elastography, in patients with NAFLD. Serum MMP7 levels were measured in a cohort of 228 patients with NAFLD. Associations between MMP7, liver stiffness measurement (LSM), ELF score and clinical parameters were determined using logistic regression modelling. Serum MMP7 was associated with clinically significant fibrosis (LSM ≥ 8.2), independent of age, gender, BMI and diabetes. The addition of MMP7 significantly improved the diagnostic performance of the ELF test, particularly in patients over the age of 60. Combinations of serum biomarkers have the potential to improve the sensitivity and specificity of detection of advanced fibrosis in at-risk patients with NAFLD. We have demonstrated that serum MMP7 is independently associated with clinically significant fibrosis and improves the diagnostic performance of currently available tests in older patients.Katharine M. IrvineSatomi OkanoPreya J. PatelLeigh U. HorsfallSuzanne WilliamsAnthony RussellElizabeth E. PowellNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Katharine M. Irvine Satomi Okano Preya J. Patel Leigh U. Horsfall Suzanne Williams Anthony Russell Elizabeth E. Powell Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
description	Abstract Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population globally. Since liver fibrosis is the most important predictor of liver-related complications in patients with NAFLD, identification of patients with advanced fibrosis among at-risk individuals is an important issue in clinical practice. Transient elastography is the best evaluated non-invasive method used in referral centres to assess liver fibrosis, however serum-based tests, such as the Enhanced Liver Fibrosis (ELF) score, have a practical advantage as first-line tests due to their wider availability and lower cost. We previously identified matrix metalloproteinase 7 (MMP7) as a serum biomarker of histological advanced fibrosis in a mixed-etiology patient cohort. In this study we aimed to determine the association between MMP7 and fibrosis, assessed by transient elastography, in patients with NAFLD. Serum MMP7 levels were measured in a cohort of 228 patients with NAFLD. Associations between MMP7, liver stiffness measurement (LSM), ELF score and clinical parameters were determined using logistic regression modelling. Serum MMP7 was associated with clinically significant fibrosis (LSM ≥ 8.2), independent of age, gender, BMI and diabetes. The addition of MMP7 significantly improved the diagnostic performance of the ELF test, particularly in patients over the age of 60. Combinations of serum biomarkers have the potential to improve the sensitivity and specificity of detection of advanced fibrosis in at-risk patients with NAFLD. We have demonstrated that serum MMP7 is independently associated with clinically significant fibrosis and improves the diagnostic performance of currently available tests in older patients.
format	article
author	Katharine M. Irvine Satomi Okano Preya J. Patel Leigh U. Horsfall Suzanne Williams Anthony Russell Elizabeth E. Powell
author_facet	Katharine M. Irvine Satomi Okano Preya J. Patel Leigh U. Horsfall Suzanne Williams Anthony Russell Elizabeth E. Powell
author_sort	Katharine M. Irvine
title	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
title_short	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
title_full	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
title_fullStr	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
title_full_unstemmed	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
title_sort	serum matrix metalloproteinase 7 (mmp7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3622a3451cc5424a98c6081d430e546b
work_keys_str_mv	AT katharinemirvine serummatrixmetalloproteinase7mmp7isabiomarkeroffibrosisinpatientswithnonalcoholicfattyliverdisease AT satomiokano serummatrixmetalloproteinase7mmp7isabiomarkeroffibrosisinpatientswithnonalcoholicfattyliverdisease AT preyajpatel serummatrixmetalloproteinase7mmp7isabiomarkeroffibrosisinpatientswithnonalcoholicfattyliverdisease AT leighuhorsfall serummatrixmetalloproteinase7mmp7isabiomarkeroffibrosisinpatientswithnonalcoholicfattyliverdisease AT suzannewilliams serummatrixmetalloproteinase7mmp7isabiomarkeroffibrosisinpatientswithnonalcoholicfattyliverdisease AT anthonyrussell serummatrixmetalloproteinase7mmp7isabiomarkeroffibrosisinpatientswithnonalcoholicfattyliverdisease AT elizabethepowell serummatrixmetalloproteinase7mmp7isabiomarkeroffibrosisinpatientswithnonalcoholicfattyliverdisease
_version_	1718396757490008064

Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease

Ejemplares similares